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Key Points
1. A number of inherited conditions can predispose the aorta, and less commonly other 
blood vessels, to dilatation and/ or rupture.
2. Broadly speaking, these conditions are recognised as syndromic when accompanied by a 
number of systemic features or non-syndromic when the aortic dilatation appears to 
exist in isolation.
3. The commonest syndromic aortopathy is Marfan syndrome and the commonest non-
syndromic aortopathy is that which accompanies congenital bicuspid aortic valve.
4. Mutations in a number of genes have been identified, particularly in syndromic 
aortopathy.
5. Although genotype-phenotype relationships exist, the phenotypes of the syndromic 
aortopathies may have significant overlap .
6. When a syndromic aortopathy is suspected, review by a clinical geneticist is instrumental 
in characterising the clinical signs and the family history.
7. Confirmation of a diagnosis (either clinically or by gene testing) allows identification of 
individuals at increased risk of aortic sequelae who will benefit from active medical 
management.
8. Medical management is usually undertaken by a cardiologist with referral to other 
specialists (eg cardiothoracic surgeons) as appropriate.
9. At risk family members should be offered predictive testing if a mutation is identified, 
and should otherwise be screened in keeping with the presumptive clinical diagnosis and 
assessment of risk.
10. Pregnancy and the post-partum period confer a higher risk for aortic complications: 
a. Women with a personal or family history of aortopathy need appropriate pre-
conception screening and counseling. 
b. Intervention may be required pre-conception and they should be managed closely 
throughout pregnancy, ideally in a high-risk obstetric clinic. 
c. Management may include appropriate cessation and commencement/continuation 
of medication ((ACE inhibitors and ARB are teratogenic and contraindicated in 
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pregnancy, beta blockers can be used in pregnancy) and should include involvement 
of a cardiologist in the management and decision making for delivery.
11. A clinical diagnosis of an inherited aortopathy can be made in the absence of a positive
genetic test if the systemic features are consistent with a specific syndromic aortopathy. 
A familial history of aortic dissection in the absence of both a positive gene test and 
systemic examination findings may be more difficult to manage without a working clinical 
diagnosis. However, an inherited risk of dissection should nonetheless be considered in 
this setting, particularly if the process has affected young individuals and/or in the 
absence of traditional risk factors.
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Introduction
The aortopathies encompass a number of conditions that result in an aorta that is structurally 
more susceptible to both dilatation and/or dissection. There is no accepted definition for the 
term and it is broadly applicable to both inherited and acquired conditions. This update 
concentrates on the inherited syndromic and non-syndromic aortopathies. Acquired thoracic and 
abdominal aortic aneurysm and dissection occur particularly in the elderly; are associated with 
cardiac risk factors, especially hypertension and cigarette smoking; and not considered further in 
this document [1-3].  This update is intended as an overview, not an exhaustive literature review. 
Where guidelines exist, regardless of the often-limited evidence base, these will be 
recommended. Extensive discussion of each condition is also beyond the scope of the update and 
interested readers may find the references a useful resource.
Clinical Characteristics
1. Syndromic aortopathies
This term includes, and this update will briefly discuss, Marfan syndrome (MFS), Turner syndrome 
(TS), Loeys Dietz syndrome (LDS), Ehlers-Danlos, particularly type IV (vascular subtype), and 
arterial tortuosity syndrome (ATS).
Most of these conditions are characterised by autosomal dominant inheritance. Turner syndrome 
is due to sex chromosome aneuploidy with the loss of one of the X chromosomes (45,X). Arterial 
tortuosity syndrome is a rare autosomal recessive condition.
2. Clinical presentation
The most serious complication of an aortopathy is an aortic dissection. Aortic dissection due to an 
underlying heritable disorder (whether syndromic or non-syndromic) presents in the same way as 
aortic dissection in the general community. Guidelines are available regarding investigation, 
diagnosis and treatment of this potentially life-threatening complication [4].
Consideration of an underlying heritable disorder should be given particularly in the setting of 
occurrence at a young age (<50), dissection during pregnancy or post-partum, when clinical 
examination uncovers clinical signs in keeping with one of the syndromic conditions (see below),
or when there is a family history of dissection. A positive family history is an important clue. 
Taking a full family history is an essential part of clinical care, including following an emergent 
presentation.
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The conditions that cause syndromic aortopathies may present to the clinician in a variety of 
other clinical settings reflecting other affected organ systems. It is important to note that the
clinical features described below can occur in a spectrum from mild to severe, and a clinical 
cardiac genetic service may be best placed to make a detailed assessment of the patient and 
family.
Syndromic Aortopathies
1. Marfan syndrome (MFS)
This is the best known and characterised inherited aortopathy. It is also the one most often 
genotypically positive in the setting of clinically diagnostic features. The revised Ghent Criteria [5]
(see Table 1 below) allows a diagnosis to be made according to the presence or absence of family 
history and taking into account the aortic root size, ectopia lentis, a number of systemic features 
and the identification of an FBN1 mutation.
Table 1: Revised Ghent Criteria for diagnosis of Marfan syndrome (MFS) (see original article for 
description of differential diagnoses [5])
No family history (a) Family history (b)
1. AoD (Z ≥ 2) and EL = MFS 1.  EL + FH* MFS = MFS
Diagnosis of MFS 2. AoD (Z ≥ 2) and FBN1 = MFS 2. Syst ≥ 7 = MFS + FH* MFS = MFS
3. AoD (Z ≥ 2) and Syst ≥ 7 = MFS 3. AoD (Z ≥ 2 if adult, Z ≥ 3 if < 20 
yoa + FH* MFS = MFS
4. EL + FBN1 + known AR = MFS
Clinical sign Score
1. Wrist + Thumb sign 3
2. Wrist OR Thumb sign 1
3. Hindfoot deformity 2
Systemic (syst) 4. Flat feet 1
features and 
scores 5. Pneumothorax 
2
for each feature 6. Myopia (> 3 dioptres) 1
(maximum 20) 7. Mitral valve prolapse 1
8. Facial features (≥ 3/5) 
(dolicopcephaly, enopthalmus, 
downslanting palpebral fissures, 
malar hypoplasia, retrognathia)    
1
9. Pectus carinatum 2
10. Pectus excavatum or chest 
asymmetry
1
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11. 11. Reduced US/LS AND 
increased AS/Ht (in the absence of 
severe scoliosis)                 
1
12. Scoliosis, thoracolumbar kyphosis 1
13.  Reduced elbow extension    1
14. Skin striae      1
15. Dural ectasia 2
16. Protrusio acetabuli    2
FH* = Family history of MFS, where diagnosis fulfils criteria in column titled (a)
AoD = aortic root dilatation 
Z = Z-score, derived from the internet z score calculator: http://www.marfan.org
Syst = systemic features
EL = ectopia lentis
FBN1 = fibrillin-1 mutation
yoa = years of age
US/LS = upper span: lower span ratio
AS/Ht = arm span: height ratio
2. Loeys Dietz syndrome (LDS)
Loeys Dietz syndrome was described recently, and clinically may appear as MFS or a marfanoid-
like condition. It is now understood to be a clinical continuum due to dysregulation of TGF beta 
(TGFβ) signalling. Clinical features are present in the vascular, skeletal, craniofacial and cutaneous 
systems [6]. The vascular disease is widespread and manifests as arterial tortuosity, aneurysm 
formation and dissection. Early reports suggesting almost ubiquitous aortic root dilatation likely 
reflect ascertainment bias [6]. Skeletal involvement overlaps with the skeletal features of MFS
and additionally may manifest as early onset osteoarthritis. Craniofacial features include 
hypertelorism, bifid uvula (see Figure 1), cleft palate, craniosynostosis and structural brain 
anomalies. Intellectual disability has been reported in severely affected children. Cutaneous 
features include hyperelastic and/or translucent skin, easy bruising and dystrophic scars.
Figure 1: Bifid uvula[d1]
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(Image taken with patient consent)
3. Ehlers Danlos syndrome (EDS)
The Ehlers Danlos syndromes are characterised by joint hypermobility, skin hyperextensibility and 
tissue fragility [7]. Ehlers Danlos syndromes Type IV (vascular subtype), is associated with rupture 
of organs and normally sized blood vessels, including the aorta [8]. Clinically, important clues are 
a history of an arterial/ intestinal/ uterine rupture, incidentally noted organ tissue fragility at 
operation and extensive easy bruising and translucent (thin) skin. Guidelines recommend surgical 
intervention in EDS Type IV only in the setting of life-threatening complications due to the 
increased surgical risk [4]. Aortic dilatation has been reported in the classic and hypermobile 
subtypes. However, most subtypes of EDS are a more benign condition with respect to aortic 
dissection risk [9]. The rarer (autosomal recessive) kyphoscolitic subtype of EDS has also been 
associated with vascular rupture[8].
4. Arterial tortuosity syndrome (ATS)
This is a very rare condition with marfanoid appearance, cutis laxa, hyperelastic soft skin, joint 
hypermobility and dislocations and herniae. Imaging reveals more widespread and tortuous 
involvement of the arterial tree [10].
5. Turner syndrome (TS)
Turner syndrome is characterised by a woman of short stature who may present with delayed 
puberty and either reduced fertility or infertility. The incidence of bicuspid aortic valve (BAV) and 
coarctation of the aorta, as well as hypertension, are overrepresented in these women [11, 12].
6. Other
A number of other genetic syndromes hav  been reported in association with aortic disease, 
including but not limited to: Weill-Marchesani syndrome (ADAMTS10 and FBN1)[13]; congenital 
contractural arachnodactyly (resembles MFS, is characterised by crumpled ears, scoliosis, joint 
contractures and FBN2 mutations)[14]; Noonan syndrome (mutations in the RAS–MAPK signalling 
pathway) [15, 16]; Alagille syndrome (JAG1)[17] ; X-linked dominant periventricular nodular 
heteropia, EDS variant (FLNA)[18] and Shprintzen-Goldberg syndrome (SK1) [19]. 
Non-Syndromic Thoracic Aortic Aneurysms and Dissection (TAAD)
Non-syndromic TAAD is recognised by the clustering of aortic sequelae in a family [20]. By 
definition, the clinical phenotype is otherwise normal. To date, mutations in these families have 
been identified in a number of genes (see Table 1, below). The proportion of families who will 
have an identifiable genetic mutation is unknown. Therefore, a positive family history is always 
significant even in the absence of a putative gene mutation.
Bicuspid aortic valve associated aortic aneurysm and dissection
Bicuspid aortic valve is the commonest condition in our community (1% prevalence) that can
develop aortic dilatation and aneurysm formation (approximately 20–30% of subjects with BAV
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[21]). Though usually a sporadic finding, it can be inherited [20, 22], and thus guidelines 
recommend echocardiographic screening first-degree relatives to determine whether the aortic 
valve is bicuspid or tricuspid [23].
Clinical diagnosis
Ideally, consideration of an inherited aortopathy should prompt referral to a clinical or cardiac 
genetics service for a thorough specialised examination. Standardised examination protocols 
exist for determining the likelihood clinically of MFS [5] and EDS [24].
Assessment of the aortic root and ascending aorta is essential if there is clinical suspicion of an 
inherited aortopathy. Aortic root involvement is classically seen in MFS and EDS, but may also 
occur in the other syndromic aortopathies (Figure 1). The ascending aorta is the usual site of 
dilatation in BAV, TS and the non-syndromic aortopathies, but also may occur in other conditions, 
including MFS (Figure 2). Abdominal aortic aneurysms have been reported in both MFS and LDS. 
Involvement of vasculature throughout the body, including cerebral vessels, occurs in LDS [6, 25].
Clinical symptoms in other vascular beds should lead to directed imaging. Once a diagnosis of 
syndromic subtype is made, then imaging will need to be considered accordingly (see 
Management). It appears prudent to image the entire aorta, though no evidence regarding the 
optimal interval between screenings is available.
Involvement of other specialists will need to be considered on a case-by-case basis according to
the likely diagnosis.
Figure 1 Dilated aortic root in Marfan syndrome[d2]
Legend: Transthoracic echocardiography long axis parasternal view showing a dilated aortic root 
(4.2 cm) in a 23-year-old woman with a clinical diagnosis of MFS, awaiting genetic results (1) and 
a borderline dilated aortic root with a normally sized ascending aorta (2) in a woman with both 
clinical and genetic diagnosis (note the off axis imaging required in the setting of chest wall 
abnormalities).
1 2
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Figure 2 Dilated ascending aorta associated with a bicuspid aortic valve
[d3]
Le
gend: Transthoracic echocardiography long axis parasternal view showing a dilated ascending 
aorta (5.0 cm) in the setting of a bicuspid aortic valve with mild stenosis (mean gradient 13 
mmHg) in a 40-year-old woman. Note the relative preservation of the aortic sinus compared to 
the dilatation seen with MFS.
Family history
A detailed (three generation pedigree) family history is essential. A reported clinical or genetic
diagnosis in a family member should be verified by obtaining relevant documentation, with 
consent as appropriate.
Molecular Genetics 
Molecular confirmation of a suspected clinical diagnosis is increasingly important for guiding
patient management. As an example, an individual who looks marfanoid will have more extensive
arterial imaging screening if identified to have a SMAD3 mutation as opposed to an FBN1
mutation.
Overview
Table 2 lists the genes identified most commonly for specific clinical phenotypes. The genotype-
phenotype relationship is not absolute. Mutations in the same gene can cause variable clinical 
phenotypes.  Fulfilment of the modified Ghent criteria does not necessarily imply a diagnosis of 
MFS, as patients with LDS may fulfil these criteria as well.
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Table 2: Gene(s) most commonly identified for the different clinical ‘classical’ aortopathy 
diagnoses
Condition Gene Reference
Marfan syndrome FBN1 [26]
TGFBR2 
TGFBR1 
SMAD3 
Loeys-Dietz syndrome
TGFB2 
[25]
Ehlers Danlos syndrome (vascular subtype) COL3A1 [27]
Arterial tortuosity syndrome SLC2A10 [10]
ACTA2
Non-syndromic TAAD
MYH11* 
(Mutations in many of the genes identified in this table as 
causing syndromic aortopathy have also been identified in 
cases of non-syndromic aortopathy)
PRKG1
MYLK
[28]
      [29]
[30]
Bicuspid aortic valve# NOTCH1^ [22]
* May be associated with a patent ductus arteriosus
# Non-syndromic TAAD genes have been identified in individuals with BAV and aortic dilatation
^ Accounts for a small proportion of patients with BAV
Genetic Testing
A definitive molecular genetic diagnosis can clarify an equivocal clinical picture or result in a 
diagnosis in an apparently phenotypically normal individual. It is unknown at this stage what 
proportion of patients with these different genetic mutations will develop aortic dilatation or 
dissection. Identification of a causal mutation allows for the provision of accurate genetic 
counselling, the screening of at-risk family members and offers the possibility of accurate 
prenatal or preimplantation genetic diagnosis. 
Sanger Sequencing of Individual Candidate Genes
Sanger sequencing may be considered when there is no doubt about the clinical diagnosis. 
Despite clinical certainty however, a pathogenic mutation may not be found. Typically, exonic or 
whole-gene deletions and/or duplications are not detected by this method and require 
alternative technology e.g. quantitative PCR, long-range PCR, multiplex ligation-dependent probe 
amplification (MLPA), and chromosomal microarray (CMA) that includes the relevant 
gene/chromosome segment. There are intrinsic hurdles, not least of all cost, of Sanger 
sequencing of consecutive candidate genes compared to multi-gene panel testing.
Multi-Gene Panels
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Many clinical laboratories offer a multi-gene MFS/LDS/familial TAAD panel that includes FBN1 
and numerous other genes associated with aortic aneurysm and dissection disorders. This 
approach may be advantageous, given the known clinical and genetic heterogeneity of these 
disorders. 
Limitations of Genetic Testing
It is important to recognise that no testing method guarantees a molecular diagnosis. The 
described limitation of Sanger sequencing to detect deletions and/or duplications may also occur 
in panel testing and should be discussed with the testing laboratory as appropriate. Both 
methodologies described above may result in the finding of a variant of uncertain/ unknown 
significance (VUS). Ideally, family studies to track the VUS genotype with phenotype may assist 
with clarification. Practically, however, this can prove difficult. Whilst functional studies to 
determine the molecular effect of the mutation may assist in interpretation of a VUS, these 
studies are not readily available.
Management
Affected Individuals
Management of acute dissection is not dealt with in this document. Broadly speaking, 
management of patients at risk of aortic dilatation and dissection falls into the following 
categories:
1. Consideration of medical therapy
a. There is data regarding medical prophylaxis of aortic dilatation, largely limited to 
individuals with MFS.
b. A number of trials have shown a positive effect on reducing aortic growth with the use of 
beta blockers, angiotensin receptor blockers (ARB) or angiotensin converting enzyme 
inhibitors (ACEI) [31, 32]. We are not aware of currently available data regarding the 
effect of medical therapy on mortality.
c. Superiority of a medication class has not been established, and treatment should be 
individualised as tolerated. Future recommendations may suggest concomitant use of 
more than one class of medication.
d.
e. It is unknown whether clinicians should aim for the dose used in trials or measure effect 
on a physiological variable (e.g. heart rate at submaximal exercise) or both.
2. Surveillance for aortic dilatation
a. Usual practice is clinical review with yearly echocardiogram in MFS.
b. Six-monthly echocardiogram if the aortic root is either close to surgical threshold or has 
increased significantly in size between prior imaging interval (≥0.3 cm/year).
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c. If there is significant valvular disease (eg aortic or mitral regurgitation), then imaging 
frequency may be further individualised.
d. Computed tomography angiography or MRI of the entire aorta should be undertaken in 
MFS. The interval for repeat screening of a normally sized aorta is not stipulated in most 
publications [4, 5, 23]. The ESC Grown Up Congenital Heart Disease Guidelines suggest 
this be done on a five-yearly basis [33]. More recent ESC and AHA multimodality 
imaging guidelines suggest a three-yearly interval, but this statement is unreferenced in 
the document [34]. If relatively frequent serial imaging is to be undertaken, MRA may 
be preferable to CTA in order to minimise the risks associated with recurrent radiation 
exposure.
e. Computed tomography angiography or MRA of the entire vasculature (cerebral to pelvic) 
should be undertaken in the syndromic aortopathies where more widespread vascular 
involvement has been documented e.g. LDS, ATS.  The interval has been suggested to 
be one year in the first instance and then at least two-yearly for LDS [25], though earlier 
recommendations had been for yearly MRA [23]. Abnormal results should translate into 
an increased screening frequency and referral as appropriate. 
f. The clinical picture of non-syndromic aortopathies remains to be fully elucidated, and 
therefore the optimal extent and frequency of vascular imaging is unclear. We would 
err on the side of caution and suggest imaging the entire vasculature, at least at 
baseline, in non-syndromic individuals with a genetic mutation. 
g. The extent of imaging that should be undertaken in non-syndromic individuals in whom 
genetic testing is uninformative is unknown. 
3. Guidelines for aortic surgery
a. Current guidelines recommend consideration of aortic surgery at varying thresholds. 
These are reproduced in Table 3, below.  Recommendations for the general population 
are included as a comparator.
b. A lower threshold than in the guideline [4] has been proposed for women with TS. Data
on 20 individuals with both TS and dissection (n = 17 Type A, of which n = 16 also had a 
BAV) proposed a lower cut off at > 25mm/m2 [35].
c. Data exists in an unselected population with thoracic aneurysms linking an increase in 
indexed aortic size (adjusted to body surface area) to risk of rupture and the combined 
endpoint of rupture, dissection and death [36].
Table 3: Guideline recommendations for surgical intervention
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Surgical intervention 
recommended
ESC 2014 [4] AHA 2010, 2014* [23, 37]
MFS ≥ 50 mm > 50 mm4
≥ 45 mm1 > 40 mm if contemplating 
pregnancy
LDS Treat patients with ≥ 42 mm (TTE)
marfanoid manifestations ≥ 44–46 mm (CT)
as per MFS thresholds
TS
4.0–5.0 cm (not separated out in 
2010 guideline from other 
conditions)
> 27.5 mm/m2 (NB other 
data suggests a cut off of 
> 25mm/m2 should be 
utilised, see above)
Non syndromic 
aortopathy No specific data
2 No specific data
≥ 55 mm
4.0–5.0 cm (not separated out 
in 2010 guideline from other 
conditions)
≥ 50 mm3 2014* > 55 mm
            > 50 mm5
BAV
            > 45 mm6
General population ≥ 55 mm ≥ 55 mm
1 = Risk factors: family history of dissection, size increase > 3mm/y, severe aortic regurgitation (AR) or mitral 
regurgitation, desire for pregnancy
2= Document suggests management according to family history
3 = Risk factors: family history of dissection, hypertension, coarctation of the aorta, size increase > 3mm/y
4 = Repair if family history of aortic dissection at < 50 mm, severe AR or rapid growth >5 mm/y
5 = Risk factors: family history of dissection, growth ≥ 5 mm/y
6 = If having surgery for severe AS or AR 
d. The potential role of pre-emptive and protective surgery, utilising a Personalised External 
Aortic Root Support (PEARS) polymer mesh, remains to be established [38]. This 
procedure currently appears to be available only in the UK and Belgium.
4. Associated complications and appropriate intervention.
a. Apart from aortic complications, the inherited aortopathies may result in a number of 
other health issues, which require referral to the appropriate specialty.
5. Advice regarding exercise restriction.
a. Exercise carries risk to the aorta, therefore recommendations exist about
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i. Avoiding participation in competitive sports or undertaking strenuous or highly 
exertive exercise in patients with a diagnosis of a syndromic aortopathy and in 
individuals with a dilated aorta; [4] and
ii. Avoiding heavy weight lifting (requiring straining) in all individuals with a 
diagnosis of a syndromic or non-syndromic aortopathy or with a dilated aorta or 
a prior dissection [23, 39].
b. It is unknown whether patients who have a non-syndromic aortopathy diagnosis and a 
normal size aorta should be given the same advice, though this may be a reasonable 
approach.
c. A comprehensive table for patients is available in an article by Maron et al., which 
outlines advice regarding different types of exercise in MFS [23, 40].
d. Some clinicians exclude patients from contact sport with a risk of collision [23]. This is 
recommended by the latest guidelines (see point e., below)
e. A recent AHA/ACC Scientific Statement has been published regarding exercise advice 
to competitive athletes with aortic diseases [41]. Although the introductory statement 
explains that the guidelines apply to competitive sports, and may not apply to those 
engaged in recreational activities, it is not entirely clear how these groups are defined.
6. Pregnancy and the post-partum period confer a higher risk for aortic complications. Women 
with a personal or family history of aortopathy need appropriate pre-conception screening 
and counselling.  Although the effect of pregnancy on the aorta may be mediated by female 
sex hormones, there is no known contraindication to available hormonal or non hormonal 
contraceptives for women with aortopathy. Prenatal or preimplantation genetic diagnosis is 
available if there is an identified mutation. Aortic intervention may be required pre-
conception and these women should be managed closely throughout pregnancy, ideally in a 
high-risk obstetric clinic, with a multidisciplinary team. Management may include 
appropriate cessation and commencement/continuation of medication (ACE inhibitors and 
ARB are teratogenic and contraindicated in pregnancy, beta blockers can be used in 
pregnancy). A cardiologist should be involved in the management and decision making for 
delivery. 
7. Advice regarding other lifestyle factors [4]
 Cessation of smoking is essential.
 Prompt identification and treatment of hypertension.
 Advise against use of cocaine.
Asymptomatic Family Members
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Aortic disease tends to be asymptomatic until a complication (usually dissection) occurs. Family 
members should be assessed as to whether they are at risk. This will depend on the family history, 
the biological relationship with the affected individual and whether a clinical diagnosis plus or 
minus a genetic diagnosis has been made in the proband.
If there is a clear genetic diagnosis, then first-degree relatives should be offered predictive testing. 
If the screened relative does not have the familial mutation they can be released from screening.
We advocate erring on the side of caution with respect to screening echocardiography of at-risk 
relatives. This is advised in 
1. All family members who share the familial mutation and who therefore should be under 
clinical care, not screening. 
2. At-risk family members where a clinical genetic diagnosis exists; and 
3. At-risk family members where no clinical genetic diagnosis is made but the dissection 
occurred in a young individual without an apparent risk factor e.g. long standing 
hypertension.
Current guidelines recommend a screening interval of five years in healthy at-risk relatives.
Additionally, consideration of wider screening of the arterial tree in non-syndromic aortopathy is 
recommended, although no advice is given regarding frequency of more extensive arterial 
imaging [4]. 
Genetic Counselling and Psychological Counselling
Genetic counselling is important for any family where a familial diagnosis is being considered. The 
circumstances in which the diagnosis was first raised can influence the way in which the family 
copes with diagnostic confirmation and the possibility of genetic testing. As aortic dissection can 
be unexpected and cause the rapid demise of a previously well, young individual, there may be 
significant issues of grief, guilt and loss. Health and travel insurance, and career options may all 
be impacted by confirmation of an aortopathy diagnosis. The genetic counsellor is well placed to 
be an initial source of support and may liaise with other counsellors or psychologists to provide
ongoing support.
Pre-Natal and Preimplantation Genetic Diagnosis (PND and PGD)
Prenatal and pre-implantation diagnosis is available when a definite genetic mutation is identified 
as causative of the aortopathy syndrome in the proband. Individuals with genetic changes that 
are not definitively pathogenic (e.g. VUS) cannot be offered PND or PGD. Decision-making 
regarding PND or PGD is a very personal process, and the role of the clinician is to provide 
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information and obstetric or IVF referral, if appropriate from the genetic point of view, when 
desired by the patient.
Unresolved questions
1. The modified Ghent Criteria for MFS state that aortic size should be corrected for age and
body size and expressed as a z-score[5]. Imaging guidelines highlight the concerns that 
indexation consistently allows a greater aortic size in larger individuals [34]. In contrast, 
surgical thresholds, other than for women with TS, are all expressed as absolute values. In 
practice, the authors often consider both absolute and indexed size and utilise the most 
concerning value to determine screening interval. Absolute size, rather than indexed, still 
guides surgical referral in practice other than in very small adults. There is a lack of 
consistency between these approaches; hopefully this will be clarified with time.
2. It is likely that further genes causing TAAD will be identified in the future. 
3. Ideally, determination of genotype–phenotype correlations will allow individualised risk 
prognostication and treatment. This will require multinational and multicentre sharing of 
aortic surveillance and outcome data in a large number of individuals.
4. It is unknown whether a particular class of drug or indeed combination therapy will provide 
better morbidity and mortality benefit, and whether this will be uniform for all sub-types 
of aortopathies.
5. It is unknown whether medical therapy should commence at the time of diagnosis, 
regardless of age and aortic size. Although opinions and practices are by no means uniform 
nationally or internationally, we are aware that some experts in the field recommend 
medical treatment of an asymptomatic individual who is mutation positive in a family 
where another family member with the same mutation has had aortic dilatation and/or 
dissection.
Concluding Remarks 
The aortopathies encompass a group of phenotypically and genetically heterogeneous conditions. 
This update has described the classical clinical findings, which can be quite variable between and 
within families. Currently, management of these conditions is impacted by variable expression 
and penetrance. As such, the prediction of aortic sequelae in any affected individual is not 
possible. The finding of a VUS may complicate diagnosis and create challenges both in clinical 
management and for the patients. Best care requires comprehensive cardiological and genetic 
evaluations and investigations, with the provision of an appropriate screening plan. Rarely, even 
despite this, affected individuals may dissect without prior aortic dilatation. 
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Further Information
1. Available from the references below.
2. Marfan support groups exist in Australia and overseas, and can be accessed on the Internet.
3. Clinical and cardiac genetic services are available both in Australia and New Zealand for review 
of patients with a suspected or proven aortopathy diagnosis.
Page 18 of 20
Ac
ce
pte
d M
an
us
cri
pt
18
References
1. Pape LA, Awais M, Woznicki EM, Suzuki T, Trimarchi S, Evangelista A, et al. Presentation, 
Diagnosis, and Outcomes of Acute Aortic Dissection: 17-Year Trends From the International 
Registry of Acute Aortic Dissection. J Am Coll Cardiol. 2015;66(4):350-8.
2. Goldfinger JZ, Halperin JL, Marin ML, Stewart AS, Eagle KA, Fuster V. Thoracic aortic 
aneurysm and dissection. J Am Coll Cardiol. 2014;64(16):1725-39.
3. Saratzis A, Bown MJ. The genetic basis for aortic aneurysmal disease. Heart. 
2014;100(12):916-22.
4. Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, et al. 2014 ESC 
Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and 
chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the 
Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur 
Heart J. 2014;35(41):2873-926.
5. Loeys BL, Dietz HC, Braverman AC, Callewaert BL, De Backer J, Devereux RB, et al. The 
revised Ghent nosology for the Marfan syndrome. J Med Genet. 2010;47(7):476-85.
6. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu H, et al. Aneurysm 
syndromes caused by mutations in the TGF-beta receptor. N Engl J Med. 2006;355(8):788-98.
7. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos 
syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and 
Ehlers-Danlos Support Group (UK). Am J Med Genet. 1998;77(1):31-7.
8. Sobey G. Ehlers-Danlos syndrome: how to diagnose and when to perform genetic tests. 
Arch Dis Child. 2015;100(1):57-61.
9. Atzinger CL, Meyer RA, Khoury PR, Gao Z, Tinkle BT. Cross-sectional and longitudinal 
assessment of aortic root dilation and valvular anomalies in hypermobile and classic Ehlers-
Danlos syndrome. J Pediatr. 2011;158(5):826-30 e1.
10. Ritelli M, Chiarelli N, Dordoni C, Reffo E, Venturini M, Quinzani S, et al. Arterial Tortuosity 
Syndrome: homozygosity for two novel and one recurrent SLC2A10 missense mutations in three 
families with severe cardiopulmonary complications in infancy and a literature review. BMC Med 
Genet. 2014;15:122.
11. Turtle EJ, Sule AA, Webb DJ, Bath LE. Aortic dissection in children and adolescents with 
Turner syndrome: risk factors and management recommendations. Arch Dis Child. 
2015;100(7):662-6.
12. Matura LA, Ho VB, Rosing DR, Bondy CA. Aortic dilatation and dissection in Turner 
syndrome. Circulation. 2007;116(15):1663-70.
13. Le Goff C, Cormier-Daire V. From tall to short: the role of TGFbeta signaling in growth and 
its disorders. Am J Med Genet C Semin Med Genet. 2012;160C(3):145-53.
14. Callewaert BL, Willaert A, Kerstjens-Frederikse WS, De Backer J, Devriendt K, Albrecht B, 
et al. Arterial tortuosity syndrome: clinical and molecular findings in 12 newly identified families. 
Hum Mutat. 2008;29(1):150-8.
15. Cornwall JW, Green RS, Nielsen JC, Gelb BD. Frequency of aortic dilation in Noonan 
syndrome. Am J Cardiol. 2014;113(2):368-71.
16. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet. 
2013;381(9863):333-42.
Page 19 of 20
Ac
ce
pte
d M
an
us
cri
pt
19
17. Kamath BM, Spinner NB, Emerick KM, Chudley AE, Booth C, Piccoli DA, et al. Vascular 
anomalies in Alagille syndrome: a significant cause of morbidity and mortality. Circulation. 
2004;109(11):1354-8.
18. Reinstein E, Frentz S, Morgan T, Garcia-Minaur S, Leventer RJ, McGillivray G, et al. 
Vascular and connective tissue anomalies associated with X-linked periventricular heterotopia 
due to mutations in Filamin A. Eur J Hum Genet. 2013;21(5):494-502.
19. Doyle AJ, Doyle JJ, Bessling SL, Maragh S, Lindsay ME, Schepers D, et al. Mutations in the 
TGF-beta repressor SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm. Nat Genet. 
2012;44(11):1249-54.
20. Luyckx I, Loeys BL, Curriculum topic: The genetic architecture of non-syndromic thoracic 
aortic aneurysm. Heart. 2015;101(20):1678-84.
21. Michelena HI, Corte AD, Prakash SK, Milewicz DM, Evangelista A, Enriquez-Sarano M. 
Bicuspid aortic valve aortopathy in adults: Incidence, etiology, and clinical significance. Int J 
Cardiol. 2015;201:400-7.
22. Prakash SK, Bosse Y, Muehlschlegel JD, Michelena HI, Limongelli G, Della Corte A, et al. A 
roadmap to investigate the genetic basis of bicuspid aortic valve and its complications: insights 
from the International BAVCon (Bicuspid Aortic Valve Consortium). J Am Coll Cardiol. 
2014;64(8):832-9.
23. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE, Jr., et al. 2010 
ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management 
of patients with Thoracic Aortic Disease: a report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines, American Association 
for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of 
Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, 
Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular 
Medicine. Circulation. 2010;121(13):e266-369.
24. Malfait F, Wenstrup RJ, De Paepe A. Clinical and genetic aspects of Ehlers-Danlos 
syndrome, classic type. Genet Med. 2010;12(10):597-605.
25. MacCarrick G, Black JH, 3rd, Bowdin S, El-Hamamsy I, Frischmeyer-Guerrerio PA, 
Guerrerio AL, et al. Loeys-Dietz syndrome: a primer for diagnosis and management. Genet Med. 
2014;16(8):576-87.
26. Proost D, Vandeweyer G, Meester JA, Salemink S, Kempers M, Ingram C, et al. Performant 
Mutation Identification Using Targeted Next-Generation Sequencing of 14 Thoracic Aortic 
Aneurysm Genes. Hum Mutat. 2015;36(8):808-14.
27. Germain DP. Ehlers-Danlos syndrome type IV. Orphanet J Rare Dis. 2007;2:32.
28. Milewicz DM, Guo DC, Tran-Fadulu V, Lafont AL, Papke CL, Inamoto S, et al. Genetic basis 
of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. 
Annu Rev Genomics Hum Genet. 2008;9:283-302.
29. Guo DC, Regalado E, Casteel DE, Santos-Cortez RL, Gong L, Kim JJ, et al. Recurrent gain-of-
function mutation in PRKG1 causes thoracic aortic aneurysms and acute aortic dissections. Am J 
Hum Genet. 2013;93(2):398-404.
30. Wang L, Guo DC, Cao J, Gong L, Kamm KE, Regalado E, et al. Mutations in myosin light 
chain kinase cause familial aortic dissections. Am J Hum Genet. 2010;87(5):701-7.
31. Thakur V, Rankin KN, Hartling L, Mackie AS. A systematic review of the pharmacological 
management of aortic root dilation in Marfan syndrome. Cardiol Young. 2013;23(4):568-81.
32. Attenhofer Jost CH, Greutmann M, Connolly HM, Weber R, Rohrbach M, Oxenius A, et al. 
Medical treatment of aortic aneurysms in Marfan syndrome and other heritable conditions. Curr 
Cardiol Rev. 2014;10(2):161-71.
Page 20 of 20
Ac
ce
pte
d M
an
us
cri
pt
20
33. Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, et al. ESC 
Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur 
Heart J. 2010;31(23):2915-57.
34. Goldstein SA, Evangelista A, Abbara S, Arai A, Asch FM, Badano LP, et al. Multimodality 
imaging of diseases of the thoracic aorta in adults: from the American Society of 
Echocardiography and the European Association of Cardiovascular Imaging: endorsed by the 
Society of Cardiovascular Computed Tomography and Society for Cardiovascular Magnetic 
Resonance. J Am Soc Echocardiogr. 2015;28(2):119-82.
35. Carlson M, Airhart N, Lopez L, Silberbach M. Moderate aortic enlargement and bicuspid 
aortic valve are associated with aortic dissection in Turner syndrome: report of the international 
turner syndrome aortic dissection registry. Circulation. 2012;126(18):2220-6.
36. Davies RR, Gallo A, Coady MA, Tellides G, Botta DM, Burke B, et al. Novel measurement 
of relative aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac Surg. 
2006;81(1):169-77.
37. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 3rd, Guyton RA, et al. 2014 
AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the 
American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 
Circulation. 2014;129(23):e521-643.
38. Treasure T, Takkenberg JJ, Golesworthy T, Rega F, Petrou M, Rosendahl U, et al. 
Personalised external aortic root support (PEARS) in Marfan syndrome: analysis of 1-9 year 
outcomes by intention-to-treat in a cohort of the first 30 consecutive patients to receive a novel 
tissue and valve-conserving procedure, compared with the published results of aortic root 
replacement. Heart. 2014;100(12):969-75.
39. Hatzaras I, Tranquilli M, Coady M, Barrett PM, Bible J, Elefteriades JA. Weight lifting and 
aortic dissection: more evidence for a connection. Cardiology. 2007;107(2):103-6.
40. Maron BJ, Chaitman BR, Ackerman MJ, Bayes de Luna A, Corrado D, Crosson JE, et al. 
Recommendations for physical activity and recreational sports participation for young patients 
with genetic cardiovascular diseases. Circulation. 2004;109(22):2807-16.
41. Braverman AC, Harris KM, Kovacs RJ, Maron BJ. Eligibility and Disqualification 
Recommendations for Competitive Athletes with Cardiovascular Abnormalities: Taskforce 7: 
Aortic diseases, including Marfan Syndrome. A Scientific Statement from the American Heart 
Association and American College of Cardiology. Circulation. 2015;132. Epub November 2, 2015.
